에스티큐브

052020KOSDAQ기계장비 및 관련 물품 도매업

47.3 / 100

Reference Date: 2026-06-10

Financial Score8.0 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 44.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

STCube operates in biopharmaceuticals and cosmetics distribution, with its innovative immunotherapy drug 'Nelmastobart' showing promising clinical results. The company's own brand 'Scenearth' is expanding globally, while industrial lens module distribution contributes significantly to revenue.

Number of Employees

16people

Average Salary

66.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 10.164.0Point

PBR

9.90Industry Average 0.640.0Point

15.5x industry avg (risky)

ROE

-26.20Industry Average 2.780.0Point

Well below industry avg

Debt Ratio

19.56Industry Average 6.760.0Point

2.9x industry avg (risky)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲27.8% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -38.6% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
에스티큐브, 전이성 대장암 2상 중간결과 "무진행 생존기간 5.6개월"
에스티큐브의 전이성 대장암 치료제 넬마스토바트 병용요법이 임상 2상 중간 분석에서 우수한 무진행 생존기간을 보여주며 긍정적인 결과를 발표했다.
Positive
에스티큐브 "면역관문, 암환자 선별 가능성 제시"
에스티큐브의 BTN1A1 단백질이 대장암 환자 선별에 혁신적 가능성을 제시하여 긍정적인 시장 반응을 이끌어냈다.
Positive
에스티큐브, ASCO서 전이성 대장암 임상 2상 중간 결과 발표
에스티큐브의 ASCO 발표에서 전이성 대장암 치료제 넬마스토바트의 긍정적 임상 중간 결과가 발표되어 주가 상승 기대.

Detailed Momentum

52-week position3.0Point

52w lower range (25%)

Current 10,500Won52-week high 22,10052-week low 6,570

1-month return0.0Point

1m -44.74% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15